Blog Archives

Black Gorilla, Big N Hard, Rize N Shine, and the likes: Fraudulent health business

November 05, 2017 – The commercial names are creative, no doubt, and we like particularly “Black Gorilla”. However, time and time again, health authorities all over have to issue foreign product alerts, warning consumers, patients, and the public at large about products that claim to be “all natural”

Read more ›

Tags: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , ,

Synthetic cannabinoids unauthorized: Brainfreeze

August 26, 2017 – Health Canada is advising Canadians of unauthorized products called Brainfreeze Potpourri or Brainfreeze Herbal Incense that are labeled as herbal products and contain synthetic cannabinoids. This product is being sold in speciality tobacco stores and head shops in Edmonton, Alberta, and may also be available for direct purchase through online retailers.

Read more ›

Tags: , , , ,

Risk of severe if not fatal skin reactions with Pembrolizumab (Keytruda)

March 21, 2017 – Health Canada just communicated this important safety information: Cases of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) under treatment of patients with Pembrolizumab (Keytruda) have been reported internationally in the clinical trials and post-marketing setting.

Read more ›

Tags: , , , , , ,

Patient Safety: Contraindication for Riociguat (Adempas)

August 16, 2016 – Riociguat (Adempas) is a stimulator of soluble guanylate cyclase (sGC). In Canada, it is approved for and indicated in the treatment of pulmonary hypertension (PH) in three forms: inoperable chronic thromboembolic pulmonary hypertension, persistent or recurrent chronic thromboembolic pulmonary hypertension after surgical treatment,

Read more ›

Tags: , , , , , ,

Rituximab [Rituxan] – Fatal Infusion Related Reactions in Patients with Rheumatoid Arthritis

June 6, 2011 – Today, we learn from Health Canada the following very important safety information:

Hoffmann-La Roche Limited, in consultation with Health Canada, would like to inform you of important new safety information regarding fatal infusion related reactions following the use of RITUXAN® (rituximab) in RA patients. 

Read more ›

Tags: , ,

Health Canada: Status of Rosiglitazone Drugs [Avandia, Avandamet, and Avandaryl] in Canada

July 15, 2010 – In the light of recently published scientific studies and an upcoming U.S. Food and Drug Administration (FDA) Advisory Committee meeting examining the heart-related (cardiovascular) safety of the diabetes drug rosiglitazone, Health Canada is informing health care professionals and Canadians of the current status of this drug in Canada.

Read more ›

Tags: , , ,

thasso: community

thasso: conditions

thasso post: magazine

View my Flipboard Magazine.

thasso: follow us

thasso: chat

You must be a registered user to participate in this chat.

thasso: tweets

thasso: categories

thasso: archives

Top